Comparison of Neurite Outgrowth Induced by Erythropoietin (EPO) and Carbamylated Erythropoietin (CEPO) in Hippocampal Neural Progenitor Cells.
10.4196/kjpp.2012.16.4.281
- Author:
Dong Hoon OH
1
;
In Young LEE
;
Miyeon CHOI
;
Seok Hyeon KIM
;
Hyeon SON
Author Information
1. Department of Psychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul 133-791, Korea.
- Publication Type:Original Article
- Keywords:
Carbamylated erythropoietin;
Erythropoietin;
Hippocampus;
Neurogenesis
- MeSH:
Adult;
Animals;
Anxiety;
Atrophy;
Bromodeoxyuridine;
Dendrites;
Dentate Gyrus;
Depression;
Erythropoietin;
Hippocampus;
Humans;
Male;
Mice;
Neurites;
Neurogenesis;
Neurons;
Spine;
Stem Cells
- From:The Korean Journal of Physiology and Pharmacology
2012;16(4):281-285
- CountryRepublic of Korea
- Language:English
-
Abstract:
A previous animal study has shown the effects of erythropoietin (EPO) and its non-erythropoietic carbamylated derivative (CEPO) on neurogenesis in the dentate gyrus. In the present study, we sought to investigate the effect of EPO on adult hippocampal neurogenesis, and to compare the ability of EPO and CEPO promoting dendrite elongation in cultured hippocampal neural progenitor cells. Two-month-old male BALB/c mice were given daily injections of EPO (5 U/g) for seven days and were sacrificed 12 hours after the final injection. Proliferation assays demonstrated that EPO treatment increased the density of bromodeoxyuridine (BrdU)-labeled cells in the subgranular zone (SGZ) compared to that in vehicle-treated controls. Functional differentiation studies using dissociated hippocampal cultures revealed that EPO treatment also increased the number of double-labeled BrdU/microtubule-associated protein 2 (MAP2) neurons compared to those in vehicle-treated controls. Both EPO and CEPO treatment significantly increased the length of neurites and spine density in MAP2(+) cells. In summary, these results provide evidences that EPO and CEPO promote adult hippocampal neurogenesis and neuronal differentiation. These suggest that EPO and CEPO could be a good candidate for treating neuropsychiatric disorders such as depression and anxiety associated with neuronal atrophy and reduced hippocampal neurogenesis.
